GH Receives FDA Approval for Guardant360 Liquid Assay on Smart Platform - ASP and Tissue Growth Upside

Research evidence excerpt

GH Receives FDA Approval for Guardant360 Liquid Assay on Smart Platform - ASP and Tissue Growth Upside

d certain of our affiliates conduct an investment management business, trade

for their own accounts, and may make investment decisions that are inconsistent with the recommendations or views expressed in this research.

We and our affiliates, officers, directors, and employees, excluding equity and credit analysts, will from time to time have long or short positions in, act as

principal in, and buy or sell, the securities or derivatives, if any, referred to in this research. We and our affiliates also may sell to or buy from customers on a

principal basis the securities described herein. We and our affiliates also do business with, or that relates to, companies covered in Guggenheim research

and may have a position in the debt of the company or companies discussed herein.

This research is not an offer to sell or the solicitation of an offer to buy any security. It does not constitute a personal recommendation or take into account

the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation

in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of

investments referred to in this research and the income from them will fluctuate. Past performance is not a guide to future performance, future returns are

not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income

derived from, certain investments.

This communication does not constitute an offer of Shares to the public in the United Kingdom.